08:00 , Dec 6, 2010 |  BC Week In Review  |  Clinical News

Aeterna Zentaris preclinical data

In mouse xenograft models of colon, lung, prostate and endometrial cancers, 45 mg/kg/day oral AEZS-129 for 4 weeks significantly inhibited tumor growth vs. vehicle-treated controls (p<0.05 for all). AEZS-129 is an oral phosphoinositide 3-kinase (PI3K)...